BTT-3033 is an orally active conformation-selective inhibitor of alpha2beta1 (EC50: 130 nM) by binding to the alpha2I domain. BTT-3033 inhibits platelet binding to collagen I and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease[1][2][4].
Molecular Weight:
465.50
Purity:
96.57
CAS Number:
[1259028-99-3]
Formula:
C23H20FN5O3S
Target:
Apoptosis,Integrin
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
